2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2711

Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2481

Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2338

Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2510

Validation of the Modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) as a Tool to Assess Axial PsA

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2551

Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Tests (CAT) in a Canadian Cohort of Patients with Systemic Lupus Erythematosus

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2456

Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2104

Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2683

Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2534

Vitamin D Reduces Cardiovascular Risk Factors in SLE

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2211

What Are the Consequences of Spinal Ankylosis on the Bone Trabecular Fragility Assessed on CT- scan in Patients with Ankylosing Spondylitis?

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2244

What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2511

What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2186

What Is an Important Difference in Gait Speed in Adults with Knee Osteoarthritis?

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1979

What Is the Pathogenic Meaning of Chondrocyte Hypertrophy in Osteoarthritis? Effect of Evc Deletion Through Hedgehog Signaling

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2088

When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].